An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation
Article in Pharmaceutics (April 2024)
The most recent citing publications are shown below. View all 13 publications that cite this research output on Dimensions.
Landiolol for heart rate control in patients with septic shock and persistent tachycardia A multicenter Randomized Clinical Trial (Landi-SEP)
Preprint in Research Square (March 2024)
Landiolol for Treating Arrhythmias: A State-of-The-Art Review.
Article in Cardiology in Review (March 2024)